Wenyan Zhou

Ms. Wenyan Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WZWenyan Zhou
Wenyan Zhou
HYHaozhe Yu
Haozhe Yu
YFYun Feng
Yun Feng
Keratoconus (KC) is a progressive corneal disorder characterized by thinning and protrusion, mostly of the inferotemporal and central corneal regions. Dysfunction of the meibomian gland, the excretions of which form the lipid layer of the tear film, has been reported to be associated with KC. Thus, this manuscript investigates the correlation among lipid layer thickness (LLT), partial blink rate (PBR), and KC of different degrees. This retrospective study included 54 patients and 24 healthy controls. The anterior corneal curvature, LLT, and PBR were taken from the unilateral eye of all 78 participants. The difference in those ocular parameters between the moderate and severe groups and the control group is significant. No significant association was found between anterior corneal curvature and LLT (r = −0.2, p = 0.15) across all the patients. However, there was a significant negative correlation between anterior corneal curvature and LLT in moderate (r = −0.6, p < 0.05) and severe (r = −0.7, p < 0.05) keratoconus cases. The results also show a significant negative correlation between anterior corneal curvature and PBR (r = −0.41, p < 0.05). Therefore, we conclude that the severity of keratoconus is associated with the thinning of LLT and the reduction of PBR. This may relate to a further epithelial abnormality with the reduced protection of tear film from the air, leading to the release of proteolytic enzymes that degrade stromal collagen and weaken the cornea.

7 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
TLTian Liu
Tian Liu
WZWenyan Zhou
Wenyan Zhou
YZYan Zhu
Yan Zhu
WXWeiyi Xia
Weiyi Xia
JCJiali Chen
Jiali Chen
ZLZhanguo Li
Zhanguo Li
Behçet’s syndrome (BS), a chronic vasculitis, leads to recurrent oral ulcers, severely impacting quality of life. Here we report the results of a randomized, double-blind, placebo-controlled trial (NCT04065672) to evaluate the efficacy and safety of low-dose interleukin-2 (LD-IL-2) in BS patients. 60 participants with active oral ulcers are randomly assigned to receive LD-IL-2 or placebo. The primary endpoint is the oral ulcer count at week 12. The LD-IL-2 group has significantly fewer oral ulcers than the placebo group (0.69 ± 1.05 vs. 1.57 ± 0.90, P = 0.001) with greater improvements in ulcer pain, disease activity, and quality of life. No infections or severe adverse events are observed in either group. LD-IL-2 expands regulatory T (Treg) cells and decreased the ratio of effector T cell to Treg cells. Thus, LD-IL-2 therapy might be an effective and safe treatment in BS patients and is associated with the modulation of CD4 + T cell populations.

21 October 2022 in Medicine
Verified
Journal Article
Open access
WZWenyan Zhou
Wenyan Zhou
TLTian Liu
Tian Liu
XXXian Xiao
Xian Xiao
JHJing He
Jing He
Rationale: Behçet’s disease (BD) is an autoimmune disease presented with recurrent oral aphthous ulcers, genital ulcers, uveitis and skin lesions. The cutaneous manifestations are often refractory and more resistant to conventional therapy. This report provides a new treatment of low-dose interleukin-2 (IL-2) with refractory BD patient. Patient concerns: A 37-year-old female patient experienced oral ulcer and erythema nodosum on the right leg for over 12 months and resisted to Methylprednisolone and Thalidomide. Diagnoses: The patient suffered from recurrent painful oral ulceration and an erythema nodosum. Pathergy test is also positive. Thus, we diagnosed her as BD according to the International Criteria for Behçet’s Disease (ICBD). Interventions: The patient took Methylprednisolone 8 mg qd, Thalidomide 50 mg qn and Hydroxychloroquine 200 mg bid successively as treatment. However, the medicine didn’t take effect. Finally, this patient was given low-dose IL-2 intramuscular injection qod for 3 months. Outcomes: Oral ulcers and the erythema disappeared and the patient has been symptom-free for 6 months. Lessons: low-dose IL-2 is a safe and effective treatment for refractory BD.